Introduction
============

Peripheral neuropathy affects up to 50% of patients with diabetes and is characterized by pain, paresthesia, and sensory loss, increasing the risk for foot problems that can result in amputation.[@b1-por-4-027] Diabetic peripheral neuropathic pain (DPNP) is generally diagnosed and managed in the primary care setting in the United Kingdom (UK), but it can be difficult for general practitioners (GPs) to recognize, because patients often do not relate pain to diabetes and, therefore, do not volunteer information on their pain symptoms during consultations.[@b2-por-4-027] DPNP is associated with impaired patient functioning and quality of life, as well as higher societal and health care costs compared to patients with diabetes but without neuropathic pain.[@b3-por-4-027],[@b4-por-4-027]

Prevalence rates of DPNP in Europe range from 8%--26% in different diabetes patient populations.[@b5-por-4-027]--[@b11-por-4-027] In the UK, the prevalence of DPNP in the diabetes population ranges from 10%--26%, depending on the criteria used to assess/define DPNP and the patient population studied.[@b5-por-4-027]--[@b7-por-4-027]

Incidence of DPNP has been less well-studied, but it is an important measure within the general population to inform health policy for screening and detection and to plan health care resources. A study, using the UK General Practice Research Database (GPRD), estimated the incidence of DPNP at 15.3 cases per 100,000 person-years in the UK primary care population between 1992 and 2002,[@b12-por-4-027] increasing to 27.2 cases per 100,000 person-years between 2002 and 2005.[@b13-por-4-027]

In the UK, clinical practice guidelines for patients with diabetes include annual checks for neuropathic symptoms and appropriate pain management plans to improve patient outcomes.[@b2-por-4-027],[@b14-por-4-027] Annual screening of all diabetes patients for neuropathy and a foot examination (including assessment of peripheral pulses and sensation) is part of the Quality Outcome Framework (QOF), a financial incentive scheme for GP practices introduced in 2004.[@b15-por-4-027]

Up-to-date DPNP incidence rates will inform health care providers and practitioners on the impact of clinical guidelines and neuropathic screening on the diagnosis and treatment patterns of DPNP in UK primary care; such information is captured in the GPRD.

The objectives of our study were to use the GPRD to determine the impact of the introduction of national guidelines[@b14-por-4-027] on the incidence of DPNP in the UK primary care population in the last 9 years and to examine trends in the incidence rate over the study period (2002--2011). In addition, we describe the characteristics of the primary care patients with incident DPNP and their initial pharmacological treatment, and we determined the proportion of patients with incident DPNP who had previously been screened for neuropathic symptoms.

Material and methods
====================

Data source
-----------

This study used a retrospective cohort design to identify incident cases of DPNP in the UK GPRD between July 1, 2002--June 30, 2011. GPRD records for \>5 million currently registered patients meet the GPRD standards of acceptable quality for use in research, which is equivalent to approximately 8.5% of the UK population.[@b16-por-4-027] Recent systematic reviews have confirmed the validity of medical diagnoses and quality of information on the GPRD.[@b17-por-4-027],[@b18-por-4-027]

Study population and study cohort with incident DPNP
----------------------------------------------------

The total study population included all patients who were permanently registered at one of the GP practices contributing to the GPRD system at any time during the 9-year study period (July 1, 2002--June 30, 2011) and who provided acceptable-quality data as recorded in the GPRD. For each patient, the period of observation was from a start date to an end date. The start date was defined as the last of either: (1) the start of the study period (July 1, 2002); (2) the patient's date of registration with the practice; or (3) the date the practice was considered "up to standard" by the GPRD. The end date was defined as the first of the following: (1) end of the study period (June 30, 2011); (2) death; (3) transfer out of the practice; or (4) the final data collection.

The study cohort with incident DPNP was identified from the total population and included those who had a GPRD record containing one of the following: a diagnosis of DPNP; a diagnosis of diabetic neuropathy with a prescription for treatment for pain current at the date of diagnosis; a diagnosis of diabetes and neuropathic pain; and a diagnosis of both diabetes and neuralgia plus a treatment for pain current on the data of the neuralgia code. Prescription for treatment for pain includes antidepressants, anticonvulsants, narcotics, nonnarcotics, and nonsteroidal anti-inflammatory drugs (NSAIDs). All diagnoses were identified based on Read codes ([Table S1](#SD1-por-4-027){ref-type="supplementary-material"} and [Table S2](#SD2-por-4-027){ref-type="supplementary-material"}). Patients were excluded from the study cohort if they had a DPNP diagnosis in their record prior to the incident date, which was defined as the date of the first DPNP diagnosis recorded in the GPRD during the study period. They were also excluded if they had fewer than 12 months of computerized data prior to the incident date or data not considered of acceptable quality by the GPRD.

[Figure 1](#f1-por-4-027){ref-type="fig"} presents the flow chart for identification and selection of the study cohort with incident DPNP in the GPRD.

Data collected
--------------

Data on patient age and sex were collected from the GPRD for the total eligible population (n = 7,483,143) and for the study cohort with incident DPNP (n = 6,779).

For the study cohort, information was collected on the most common diabetes-related comorbidities (cardiovascular disease, cerebrovascular and peripheral vascular disease, retinopathy, hypoglycemic event, other metabolic diseases, skin problems, nephropathy, obesity, and anxiety) and pain-related comorbidities (lower back pain, osteoarthritis, fibromyalgia syndrome, migraine, psoriatic arthropathy, and rheumatoid arthritis). Items from the Charlson Comorbidity Index (CCI) were identified using 17 previously defined categories of comorbid conditions based on Read codes.[@b19-por-4-027] The frequency and percentage of these comorbidities in the 12 months before the incident date were estimated; and the CCI score, a summary measure of index that represents the 1-year mortality for patients based on their history of a range of comorbid conditions, was calculated for each patient.

Information on initial treatment for DPNP was collected within 28 days of the first record of the DPNP diagnosis (incident date) during the study period for: tricyclic antidepressants (TCAs); selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs); other antidepressants; anticonvulsants; opioids; nonnarcotics; and NSAIDs. The frequency and percentage of each type of drug were estimated. If more than one pharmacotherapy was prescribed on the same day, the initial treatment was considered to be a combination of these therapies.

The frequency and percentage of patients who underwent screening for neuropathic symptoms during the study period were determined by examining Read codes for diabetic peripheral neuropathy screening and diabetic foot examination/screen ([Table S3](#SD3-por-4-027){ref-type="supplementary-material"}). The number/percentage of patients diagnosed with DPNP after neuropathic screening during the study period was calculated.

Analysis
--------

To replicate the methodology of Hall et al,[@b12-por-4-027] the incidence rate of DPNP per 100,000 person-years of observation was calculated for the total study period and for the three 3-year subperiods: (1) July 1, 2002--June 30, 2005; (2) July 1, 2005--June 30, 2008; and (3) July 1, 2008--June 30, 2011. The incidence of DPNP was also estimated by sex and age groups (0--14, 15--29, 30--44, 45--59, 60--74, 75+ years). The age group for each patient was determined using a reference year, which was either the start of the study period (2002 for the total study period as well as the first subperiod; 2005 for subperiod 2; and 2008 for subperiod 3), or the date of entry into the GPRD if this occurred later than the start of the study period. Confidence intervals (95% CI) for incidence rates were calculated based on Poisson exact CI. The incidence rates of DPNP for the three subperiods were compared using a Poisson regression model for each age group. The number of DPNP cases was the dependent variable, and the period indicator was included as an independent variable. Total years of observations were included as time of exposure. Results of patient characteristics, comorbidities, and medication are based on nonmissing data. All data analyses were carried out using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

The total study population eligible for analysis was almost 7.5 million patients ([Figure 1](#f1-por-4-027){ref-type="fig"}), providing approximately 38.1 million (38,118,838) person-years of observation. Of this total population, 50.9% were female, and the mean age was 35.3 years (standard deviation 23.5).

From the total study population, 6,779 patients were identified as having incident DPNP during the study period ([Figure 1](#f1-por-4-027){ref-type="fig"}), and [Table 1](#t1-por-4-027){ref-type="table"} summarizes the characteristics of this patient cohort.

The overall incidence of newly diagnosed DPNP during the whole study period was 17.8 per 100,000 person-years (95% CI = 17.4--18.2). [Table 2](#t2-por-4-027){ref-type="table"} shows that the incidence of DPNP increased with age among both men and women, but it did not change significantly over the three subperiods, except among women aged 60--74 years, where the incidence decreased in the period 2008--2011 compared with the two earlier periods (*P* = 0.001).

During the whole study period, 90,162 patients in the total study population underwent neuropathic screening. Of these patients, 3,152 (3.5%) had a diagnosis of DPNP after neuropathic screening (but were not necessarily an incident case); and 1,053 (1.2%) were identified with incident DPNP. Of the 6,779 patients in the study cohort with incident DPNP, 1,053 (15.5%) had prior neuropathic screening during the study period (n = 109 for subperiod 1, n = 388 for subperiod 2, and n = 556 for subperiod 3).

A treatment for DPNP was initiated for 5,767 (85.1%) of the patients with incident DPNP within 28 days of diagnosis, and [Table 3](#t3-por-4-027){ref-type="table"} summarizes the initial pharmacological treatment prescribed for these patients. Over the total study period, the most common single first-line treatments were TCAs (27.2%), anticonvulsants (17.0%), and NSAIDs (14.9%), with combination therapy being prescribed as the initial treatment for 26.6% of patients. There was little change in first-line medication use across the three subperiods, except for a slight decrease in the use of opioids and NSAIDs, and a very small increase in the use of SNRIs ([Table 3](#t3-por-4-027){ref-type="table"}). The most common combinations prescribed within 28 days of first diagnosis during the total study period were NSAIDs plus opioids (10.3%); TCAs, plus NSAIDs (9.6%); and TCAs plus opioids (8.6%).

Discussion
==========

In this study, the overall incidence rate of DPNP in the UK primary care population using the GPRD was 17.8 cases per 100,000 person-years over the 9-year study period from 2002--2011. This is consistent with the previously reported DPNP incident rate of 15.3 cases per 100,000 person-years for 1992--2002,[@b12-por-4-027] where the number of incident cases (per 100,000 person-years) increased over time from 12.9 for 1992--1994, to 14.4 for 1995--1997, to 19.0 for 1998--2001, to 27.2 for 2002--2005. In contrast to the previous studies by Hall et al,[@b12-por-4-027],[@b13-por-4-027] we found little change over time in the incidence of DPNP; the number of incident cases per 100,000 person-years was stable over the three consecutive 3-year periods (17.9, 17.2, and 18.4, respectively).

The total incident cases of DPNP (n = 6,779) during 2002--2011 out of 7.5 million primary care patients can be translated into a crude prevalence rate of 0.5% in the general population, based on the assumption that prevalence is approximately the product of disease incidence and average disease duration, using an assumed duration of DPNP of 5 years.[@b20-por-4-027] Although there is little information on the natural history of DPNP, it is generally believed that painful symptoms resolve or become less prominent over time while the neuropathy continues to progress.[@b21-por-4-027],[@b22-por-4-027] As of 2011, a total of 2.9 million people in the UK have been diagnosed with diabetes, giving an average diabetes prevalence rate of 4.5%.[@b23-por-4-027] Using this diabetes prevalence rate -- and assuming that DPNP occurs in 21.0% of people with diabetes based on recent data from \>15,000 UK patients with diabetes[@b5-por-4-027] -- would provide a DPNP prevalence rate of 0.9% in the general population. While the estimates from our study do not provide a definitive indication of DPNP prevalence rates in the UK, they suggest that DPNP is being underdiagnosed in UK primary care. The results of our study also indicate that general practitioners (GPs) are not prescribing first-line treatments for neuropathic pain as recommended by clinical guidelines,[@b14-por-4-027],[@b24-por-4-027] suggesting that other factors are being taken into consideration when selecting treatment for DPNP.

In clinical practice, DPNP is diagnosed based on clinical signs and symptoms, such as the type of pain, time of pain occurrence, and abnormal sensations; therefore, an accurate diagnosis relies on the patient's description of pain.[@b22-por-4-027],[@b25-por-4-027] However, patients often do not link pain to diabetes or find it difficult to describe the symptoms they are experiencing and, therefore, may not report their pain symptoms to the doctor.[@b2-por-4-027],[@b6-por-4-027],[@b22-por-4-027] This could be one reason for the underdiagnosis of DPNP in primary care, and highlights the need for physicians to gather information on pain by prompting patients for relevant information, potentially using a simple screening form.[@b26-por-4-027] The annual foot examination and/or test for neuropathy in patients with diabetes is an ideal opportunity to diagnose DPNP, and is part of the QOF scheme for GP practices in the UK, which provides a financial incentive to complete these assessments.[@b6-por-4-027] However, the annual foot screen does not include specific screening questions on pain; there is no financial incentive for providing any diagnosis (including that of DPNP) arising from the assessment. Unexpectedly, we found that only 15.5% of patients with incident DPNP had a previous diabetic peripheral neuropathy screen or foot examination recorded in GPRD. This raises questions about how accurately screening is recorded in GPRD and whether it fully captures the QOF annual screening program, although a recent survey conducted by Diabetes UK found that a quarter of patients with diabetes could not recall having had an annual foot screen.[@b27-por-4-027] Our finding that more than one-half of the incident DPNP cases with prior neuropathic screening occurred in the last subperiod (2008--2011) suggests that diagnosis of DPNP may be improving and that the QOF scheme (introduced in 2004) may be helping. However, as screening was checked for during the total study period (2002--2011), patients identified with DPNP in subperiod 3 had a longer time for screening to be recorded than the patients in subperiod 1. Nevertheless, rates of screening are low and further research over the next few years should make this clearer.

There was a low frequency (\<10%) of diabetes- and pain-related comorbidities in the 12 months before DPNP diagnosis, and the most common comorbidities were consistent with those reported previously in a retrospective database study of \>11,000 patients with DPNP.[@b28-por-4-027] Some diabetes-related comorbidities (neuropathy, obesity, low levels of high-density lipoprotein cholesterol, and high levels of triglycerides) have been identified as independent risk factors for DPNP.[@b9-por-4-027]

In our study, the majority (85.1%) of patients with incident DPNP started pain-relief medication within 28 days. The most commonly used first-line medications were TCAs, anticonvulsants, and NSAIDs -- despite a lack of evidence for NSAID efficacy in DPNP. SNRIs, such as duloxetine, were rarely prescribed as initial treatment. These findings are consistent with other studies in patients with DPNP.[@b3-por-4-027],[@b9-por-4-027],[@b12-por-4-027],[@b20-por-4-027] Interestingly, treatment patterns at the time of first diagnosis of DPNP do not seem to have changed over the 9-year study period and, even in the last 3-year period (2008--2011), only 4.0% of patients received an SNRI as their initial medication. This indicates that patients are not being treated according to current clinical guidelines, which recommend duloxetine as first-line treatment for people with painful diabetic neuropathy, or amitriptyline, if duloxetine is contraindicated.[@b14-por-4-027] It is possible that patients are being prescribed TCAs (alone, or in combination with NSAIDs or opioids) because GPs are unsure of the diagnosis, and these antidepressants are known to be cheap and effective for the treatment of many painful conditions.

This study has several limitations. First, patients with incident DPNP were identified in the GPRD using multiple diagnostic codes covering diabetes, neuropathy, and neuropathic pain, together with prescription of pain relief medication. Although this was relatively straightforward and consistent with a previous publication,[@b12-por-4-027] more accurate data collection would be achieved if there was a consistent and clear definition of DPNP, and a diagnostic code that is uniformly used to record its presence. Second, because of the inclusion criteria, patients with diabetic neuropathy or diabetes plus neuralgia and taking medication for depression or another painful condition may be included, resulting in an overestimation of the incidence of DPNP. Third, our study cohort of patients with incident DPNP does not include patients with impaired glucose tolerance (prediabetes) that may have peripheral neuropathy and/or neuropathic pain.[@b29-por-4-027] Fourth, we were not able to assess pain severity in the GPRD, which may influence the diagnosis of DPNP and prescription of pain medication. Many patients with DPNP report having severe pain,[@b7-por-4-027] and those with severe pain are more likely to receive pain treatment.[@b10-por-4-027] Increasing pain severity is also associated with poorer patient outcomes and increased health care resource use and related costs.[@b30-por-4-027]

The strengths of our study include the large sample of primary care patients from the GPRD, which is representative of the UK population and utilizes real-life data that is routinely collected and recorded during primary care consultations. Importantly, as DPNP is typically diagnosed and managed in primary care, GPRD is the most appropriate data source available in the UK. Other strengths of this study are that we used similar methodology to Hall et al,[@b12-por-4-027] and the incidence of DPNP during the 9-year study period was well-defined.

Conclusion
==========

In conclusion, our study provides up-to-date information on the incidence rate of DPNP in the UK primary care population. The incidence of DPNP increases with age and more commonly affects men, but it has remained relatively stable over the past 9 years. However, our results suggest that DPNP is underdiagnosed in UK primary care and that treatment on diagnosis does not follow clinical guidelines, indicating the need for improved awareness and education about DPNP. If GPs can provide an early and confident diagnosis of DPNP, they may be more likely to implement treatments that reflect current clinical guideline recommendations, thereby improving patient care and reducing the burden of this disease.

Supplementary tables
====================

###### 

Read codes for diabetes

  Medcode   Read code   Read term
  --------- ----------- -----------------------------------------------------------
  1038      C100011     IDDM
  15690     C103.00     DM with ketoacidotic coma
  46963     C108000     IDDM with renal complications
  57621     C108D00     IDDM with nephropathy
  4513      C109.00     NIDDM
  55842     C109200     NIDDM with neurological complications
  17262     C109600     NIDDM with retinopathy
  33343     C10y.00     DM with other specified manifestation
  1682      C101.00     DM with ketoacidosis
  53200     C101000     DM, juvenile type, with ketoacidosis
  42505     C101z00     DM NOS with ketoacidosis
  7795      C106.12     DM with neuropathy
  59365     C109C00     NIDDM with nephropathy
  63371     C10y100     DM, adult + other specified manifestation
  13279     C104y00     Other specified DM with renal complications
  56448     C108A00     IDDM without complication
  9013      66AJ.11     Unstable diabetes
  14889     C100111     Maturity onset diabetes
  41389     C105100     DM, adult onset + ophthalmic manifestation
  32556     C107.12     Diabetes with gangrene
  1647      C108.00     IDDM
  40401     C109500     NIDDM with gangrene
  2471      K01x100     Nephrotic syndrome in DM
  506       C100112     NIDDM
  16491     C106.13     DM with polyneuropathy
  67853     C106000     DM, juvenile + neurological manifestation
  49276     C108100     IDDM with ophthalmic complications
  26855     C108400     Unstable IDDM
  6509      C108700     IDDM with retinopathy
  52303     C109000     NIDDM with renal complications
  62146     C109300     NIDDM with multiple complications
  34912     C109400     NIDDM with ulcer
  63762     C10z100     DM, adult onset + unspecified complication
  64357     C10zz00     DM NOS with unspecified complication
  50609     L180600     Preexisting DM, noninsulin-dependent
  24490     C100000     DM, juvenile type, no mention of complications
  52283     C108200     IDDM with neurological complications
  29979     C109900     NIDDM without complication
  40023     C102000     DM, juvenile type, with hyperosmolar coma
  35105     C104100     DM, adult onset, with renal manifestation
  35107     C104z00     DM with nephropathy NOS
  32403     C107.11     DM with gangrene
  17858     C108.12     Type 1 DM
  52104     C108300     IDDM with multiple complications
  6791      C108800     IDDM -- poor control
  66675     C10A000     Malnutrition-related DM with coma
  31790     F372.00     Polyneuropathy in diabetes
  22967     2BBF.00     Retinal abnormality -- diabetes-related
  711       C10.00      DM
  14803     C100100     DM, adult onset, no mention of complications
  35399     C107.00     DM with peripheral circulatory disorder
  63357     C107100     DM, adult + peripheral circulatory disorder
  18505     C108.11     IDDM
  45467     C109B00     NIDDM with polyneuropathy
  52236     C10A.00     Malnutrition-related DM
  52212     Cyu2.00     \[X\] DM
  34528     3882.00     Diabetes well-being questionnaire
  50972     C100z00     DM NOS with no mention of complications
  16502     C104.00     DM with renal manifestation
  33807     C107200     DM, adult with gangrene
  5884      C109.11     NIDDM
  72320     C109A00     NIDDM with mononeuropathy
  45491     C10z.00     DM with unspecified complication
  17067     F171100     Autonomic neuropathy due to diabetes
  55431     L180X00     Preexisting DM, unspecified
  13069     66A8.00     Has seen dietitian -- diabetes
  54856     C101100     DM, adult onset, with ketoacidosis
  21482     C102.00     DM with hyperosmolar coma
  69748     C105000     DM, juvenile type + ophthalmic manifestation
  34283     C105z00     DM NOS with ophthalmic manifestation
  65025     C107z00     DM NOS with peripheral circulatory disorder
  17859     C109.12     Type 2 DM
  50429     C109100     NIDDM with ophthalmologic complications
  38986     C100.00     DM with no mention of complications
  43139     C102100     DM, adult onset, with hyperosmolar coma
  72345     C102z00     DM NOS with hyperosmolar coma
  68843     C103100     DM, adult onset, with ketoacidotic coma
  33254     C105.00     DM with ophthalmic manifestation
  16230     C106.00     DM with neurological manifestation
  39317     C106100     DM, adult onset + neurological manifestation
  44443     C108500     IDDM with ulcer
  60499     C108600     IDDM with gangrene
  31310     C108900     IDDM maturity onset
  41716     C108C00     IDDM with polyneuropathy
  8403      C109700     NIDDM, poor control
  50960     L180500     Preexisting DM, insulin-dependent
  24423     C108.13     Type 1 DM
  18219     C109.13     Type 2 DM
  24458     C109711     Type 2 DM, poor control
  42729     C108E11     Type 1 DM with hypoglycemic coma
  63017     C108911     Type 1 DM maturity onset
  44440     C108E00     IDDM with hypoglycemic coma
  62107     C109511     Type 2 DM with gangrene
  55075     C109411     Type 2 DM with ulcer
  62352     C108H11     Type 1 DM with arthropathy
  42762     C109612     Type 2 DM with retinopathy
  44779     C109E12     Type 2 DM with diabetic cataract
  10642     ZC2C800     Dietary advice for DM
  44260     C108F00     IDDM with diabetic cataract
  46850     C108811     Type 1 DM, poor control
  58604     C109611     Type 2 DM with retinopathy
  47409     C109B11     Type 2 DM with polyneuropathy
  17545     C108F11     Type 1 DM with diabetic cataract
  64571     C109C11     Type 2 DM with nephropathy
  65616     C108H00     IDDM with arthropathy
  41049     C108712     Type 1 DM with retinopathy
  66965     C109H12     Type 2 DM with neuropathic arthropathy
  60699     C109F12     Type 2 DM with peripheral angiopathy
  45914     C108812     Type 1 DM, poor control
  56268     C109D11     Type 2 DM with hypoglycemic coma
  50225     C109011     Type 2 DM with renal complications
  18278     C109 J00    Insulin-treated Type 2 DM
  48192     C109E11     Type 2 DM with diabetic cataract
  24836     C109C12     Type 2 DM with nephropathy
  37648     C109J11     Insulin-treated NIDDM
  24693     C109G00     NIDDM with arthropathy
  45919     C109212     Type 2 DM with neurological complications
  66872     C108D11     Type 1 DM with nephropathy
  70316     C109112     Type 2 DM with ophthalmic complications
  60107     C108411     Unstable type 1 DM
  45913     C109712     Type 2 DM, poor control
  47816     C109H11     Type 2 DM with neuropathic arthropathy
  18209     C109012     Type 2 DM with renal complications
  61344     C108011     Type 1 DM with renal complications
  65704     C109412     Type 2 DM with ulcer
  43785     C109D00     NIDDM with hypoglycemic coma
  18264     C109 J12    Insulin-treated Type 2 DM
  51957     C108511     Type 1 DM with ulcer
  38161     C108711     Type 1 DM with retinopathy
  67905     C109211     Type 2 DM with neurological complications
  61071     C109D12     Type 2 DM with hypoglycemic coma
  18230     C108 J12    Type 1 DM with neuropathic arthropathy
  49146     C108211     Type 1 DM with neurological complications
  36633     C109K00     Hyperosmolar nonketotic state in type 2 DM
  1549      C10E.00     Type 1 DM
  758       C10F.00     Type 2 DM
  12640     C10FC00     Type 2 DM with nephropathy
  1407      C10FJ00     Insulin-treated Type 2 DM
  18387     C10E700     Type 1 DM with retinopathy
  21983     C108012     Type 1 DM with renal complications
  69278     C109E00     NIDDM with diabetic cataract
  18642     C10EH00     Type 1 DM with arthropathy
  35385     C10FH00     Type 2 DM with neuropathic arthropathy
  54899     C109F11     Type 2 DM with peripheral angiopathy
  10418     C10ED00     Type 1 DM with nephropathy
  25041     ZC2CA00     Dietary advice for type 2 diabetes
  18496     C10F600     Type 2 DM with retinopathy
  47954     C10F900     Type 2 DM without complication
  32359     ZRbH.00     Perceived control of insulin-dependent diabetes
  18390     C10FM00     Type 2 DM with persistent microalbuminuria
  50813     C109A11     Type 2 DM with mononeuropathy
  10692     C10EM00     Type 1 DM with ketoacidosis
  39070     C10EE00     Type 1 DM with hypoglycemic coma
  70766     C108E12     Type 1 DM with hypoglycemic coma
  62674     C10FA00     Type 2 DM with mononeuropathy
  47582     C10E000     Type 1 DM with renal complications
  40837     C10EN00     Type 1 DM with ketoacidotic coma
  32627     C10FN00     Type 2 DM with ketoacidosis
  26054     C10FL00     Type 2 DM with persistent proteinuria
  35288     C10E800     Type 1 DM, poor control
  37806     C10FF00     Type 2 DM with peripheral angiopathy
  40682     C10E900     Type 1 DM maturity onset
  47649     C10E100     Type 1 DM with ophthalmic complications
  34268     C10F200     Type 2 DM with neurological complications
  44982     C10FE00     Type 2 DM with diabetic cataract
  25627     C10F700     Type 2 DM, poor control
  43921     C10E400     Unstable type 1 DM
  49074     C10F400     Type 2 DM with ulcer
  30294     C10EL00     Type 1 DM with persistent microalbuminuria
  18777     C10F000     Type 2 DM with renal complications
  12736     C10F500     Type 2 DM with gangrene
  18683     C10E500     Type 1 DM with ulcer
  36695     C10D.00     DM autosomal dominant type 2
  46301     C10EC00     Type 1 DM with polyneuropathy
  18425     C10FB00     Type 2 DM with polyneuropathy
  61829     C108212     Type 1 DM with neurological complications
  30323     C10EK00     Type 1 DM with persistent proteinuria
  46624     C10C.11     Maturity onset diabetes in youth
  54008     C10EJ00     Type 1 DM with neuropathic arthropathy
  25591     C10FQ00     Type 2 DM with exudative maculopathy
  51756     C10FP00     Type 2 DM with ketoacidotic coma
  46917     C10FD00     Type 2 DM with hypoglycemic coma
  22871     C10EP00     Type 1 DM with exudative maculopathy
  62209     C10EM11     Type 1 DM with ketoacidosis
  42831     C10E200     Type 1 DM with neurological complications
  51697     C10G.00     Secondary pancreatic DM
  47321     C10F100     Type 2 DM with ophthalmic complications
  49949     C10E411     Unstable type 1 DM
  49554     C10EF00     Type 1 DM with diabetic cataract
  18143     C109G11     Type 2 DM with arthropathy
  49869     C109G12     Type 2 DM with arthropathy
  69043     ZC2C900     Dietary advice for type 1 diabetes
  65267     C10F300     Type 2 DM with multiple complications
  59253     C10FG00     Type 2 DM with arthropathy
  51261     C10E.12     IDDM
  69993     C10E600     Type 1 DM with gangrene
  22884     C10F.11     Type 2 DM
  60796     C10FL11     Type 2 DM with persistent proteinuria
  47650     C10E300     Type 1 DM with multiple complications
  59725     C109111     Type 2 DM with ophthalmic complications
  12455     C10E.11     Type 1 DM
  69676     C10EA00     Type 1 DM without complication
  68105     C10EB00     Type 1 DM with mononeuropathy
  64668     C10FJ11     Insulin-treated type 2 DM
  55239     C10EQ00     Type 1 DM with gastroparesis
  57278     C10F011     Type 2 DM with renal complications
  49655     C10F611     Type 2 DM with retinopathy
  63690     C10FR00     Type 2 DM with gastroparesis
  47315     C10F711     Type 2 DM, poor control
  54600     C10E412     Unstable IDDM
  93468     C10EG00     Type 1 DM with peripheral angiopathy
  53392     C10F911     Type 2 DM without complication
  43227     C10F311     Type 2 DM with multiple complications
  50527     C10FB11     Type 2 DM with polyneuropathy
  45276     C10E312     IDDM with multiple complications
  66145     C10EN11     Type 1 DM with ketoacidotic coma
  72702     C10E812     IDDM, poor control
  96506     C10G000     Secondary pancreatic DM without complication
  66475     66Ak.00     Diabetic monitoring, lower risk albumin excretion
  69163     8HTi.00     Referral to multidisciplinary diabetic clinic
  62613     C10EA11     Type 1 DM without complication
  57382     7272600     Laser photocoagulation to lesion of retina NEC
  95813     9N1o.00     Seen in multidisciplinary diabetic clinic
  61021     68AB.00     Diabetic digital retinopathy screening offered
  72827     7P17100     Insulin secretion glucagon test
  64142     8Hl1.00     Referral for diabetic retinopathy screening
  84142     44V6.00     Extended glucose tolerance test
  91164     ZRB4.11     CSQ, Diabetes clinic satisfaction questionnaire
  82474     8Hl4.00     Referral to community diabetes specialist nurse
  83532     66Ao.00     Diabetes type 2 review
  83485     66Am.00     Insulin dose changed
  85660     66An.00     Diabetes type 1 review
  91646     C10F411     Type 2 DM with ulcer
  91942     C10E311     Type 1 DM with multiple complications
  91943     C10EC11     Type 1 DM with polyneuropathy
  85336     7P17.00     Diagnostic endocrinology
  90301     66Ag.00     Insulin needles changed daily
  85991     C10FM11     Type 2 DM with persistent microalbuminuria
  93380     C10N100     Cystic fibrosis-related DM
  92979     7P17z00     Diagnostic endocrinology NOS
  93390     9OLH.00     Attended DAFNE diabetes-structured education program
  93491     9OLJ.00     DAFNE diabetes structured education program completed
  93657     8Hj4.00     Referral to DESMOND diabetes structured education program
  93631     9OLL.00     XPERT diabetes-structured education program completed
  93704     8Hj3.00     Referral to DAFNE diabetes structured education program
  93727     C10FE11     Type 2 DM with diabetic cataract
  93854     9OLM.00     Diabetes-structured education program declined
  93870     8Hj5.00     Referral to XPERT diabetes-structured education program
  93875     C10E712     IDDM with retinopathy
  93878     C10E511     Type 1 DM with ulcer

**Abbreviations:** IDDM, insulin dependent diabetes mellitus; CSQ, (Diabetes) clinic satisfaction questionnaire; DM, diabetes mellitus; NEC, not elsewhere classified; NOS, not otherwise specified; NIDDM, noninsulin dependent diabetes mellitus; DAFNE, Dose Adjustment For Normal Eating; DESMOND, Diabetes Education and Self-Management for Ongoing and Newly Diagnosed.

###### 

Read codes for DPNP

  Medcode                                           Read code   Read term
  ------------------------------------------------- ----------- ------------------------------------------------------------------------
  **1. Painful diabetic neuropathy**                            
  48078                                             F372000     Acute painful diabetic neuropathy
  35785                                             F372100     Chronic painful diabetic neuropathy
  **2. Diabetic neuropathy (+ pain medication)**                
  2342                                              F372.12     Diabetic neuropathy
  5002                                              F372.11     Diabetic polyneuropathy
  16230                                             C106.00     DM with neurological manifestation
  16491                                             C106.13     DM with polyneuropathy
  17247                                             F35z000     Diabetic mononeuritis NOS
  18056                                             2G5C.00     Foot abnormality, diabetes-related
  18230                                             C108J12     Type 1 DM with neuropathic arthropathy
  22573                                             C106z00     DM NOS with neurological manifestation
  24694                                             C108B00     IDDM with mononeuropathy
  27921                                             2G51000     Foot abnormality, diabetes-related
  31790                                             F372.00     Polyneuropathy in diabetes
  41716                                             C108C00     IDDM with polyneuropathy
  42831                                             C10E200     Type 1 DM with neurological complications
  43227                                             C10F311     Type 2 DM with multiple complications
  44033                                             F345000     Diabetic mononeuritis multiplex
  45276                                             C10E312     IDDM with multiple complications
  45467                                             C109B00     NIDDM with polyneuropathy
  45919                                             C109212     Type 2 DM with neurological complications
  47409                                             C109B11     Type 2 DM with polyneuropathy
  47650                                             C10E300     Type 1 DM with multiple complications
  34152                                             G73y000     Diabetic peripheral angiopathy
  34268                                             C10F200     Type 2 DM with neurological complications
  35385                                             C10FH00     Type 2 DM with neuropathic arthropathy
  37315                                             F3y0.00     Diabetic mononeuropathy
  39317                                             C106100     DM, adult onset + neurological manifestation
  39809                                             C108J00     IDDM with neuropathic arthropathy
  54899                                             C109F11     Type 2 DM with peripheral angiopathy
  55842                                             C109200     NIDDM with neurological complications
  60208                                             C108J11     Type 1 DM with neuropathic arthropathy
  60699                                             C109F12     Type 2 DM with peripheral angiopathy
  72320                                             C109A00     NIDDM with mononeuropathy
  91942                                             C10E311     Type 1 DM with multiple complications
  7795                                              C106.12     DM with neuropathy
  11663                                             M271100     Neuropathic diabetic ulcer -- foot
  61523                                             C106y00     Other specified DM with neurological comps
  61829                                             C108212     Type 1 DM with neurological complications
  65267                                             C10F300     Type 2 DM with multiple complications
  67853                                             C106000     DM, juvenile + neurological manifestation
  67905                                             C109211     Type 2 DM with neurological complications
  98616                                             C10F211     Type 2 DM with neurological complications
  99231                                             C108B11     Type 1 DM with mononeuropathy
  101735                                            C10E212     IDDM with neurological comps
  49146                                             C108211     Type 1 DM with neurological complications
  50813                                             C109A11     Type 2 DM with mononeuropathy
  52283                                             C108200     IDDM with neurological comps
  54212                                             C109F00     NIDDM with peripheral angiopathy
  **3. Neuropathic (pain + diabetes)**                          
  35537                                             Fyu7C00     \[X\] Polyneuropathy, unspecified
  2790                                              F367.00     Peripheral neuropathy
  3958                                              F366.00     Polyneuropathy
  97306                                             Fyu7200     \[X\] Other specified polyneuropathies
  55076                                             Fyu7.00     \[X\] Polyneuropathies and other disorder of peripheral nervous system
  24226                                             F37z.11     Polyneuropathy unspecified
  **4. Neuralgia (+ diabetes + pain medication)**               
  2284                                              N242000     Neuralgia unspecified
  54992                                             N242.00     Neuralgia, neuritis, and radiculitis unspecified
  23839                                             N242z00     Neuralgia, neuritis, or radiculitis NOS

**Note:** \[X\] Cross referenced to specific ICD-10 codes (other READ terms relate to ICD-9).

**Abbreviations:** DPNP, diabetic peripheral neuropathic pain; DM, diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; NIDDM, noninsulin-dependent diabetes mellitus.

###### 

Read codes for DPNP screening

  Medcode                              Read code   Read term
  ------------------------------------ ----------- ------------------------------------------
  **1. Painful diabetic neuropathy**               
  10977                                66Ac.00     Diabetic peripheral neuropathy screening
  12247                                8I6G.00     Diabetic foot examination not indicated
  22823                                66Ab.00     Diabetic foot examination
  95994                                66Aq.00     Diabetic foot screen

**Abbreviation:** DPNP, diabetic peripheral neuropathic pain.
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###### 

Characteristics of patient cohort with incident DPNP

  Characteristic                                                                    n (%) or mean (SD)
  --------------------------------------------------------------------------------- --------------------
  Number of patients with incident DPNP during total study period                   6,779
  Sex, n (%)                                                                        
   Female                                                                           3,083 (45.5)
   Male                                                                             3,696 (54.5)
  Age, mean (SD) years at DPNP incidence                                            65.5 (12.9)
   Females                                                                          66.0 (13.5)
   Males                                                                            65.0 (12.4)
  Diabetes-related comorbidities[\*](#tfn1-por-4-027){ref-type="table-fn"}, n (%)   
   Cardiovascular disease                                                           453 (6.7)
   Cerebrovascular and peripheral vascular disease                                  595 (8.8)
   Retinopathy                                                                      484 (7.1)
  Pain-related comorbidities[\*](#tfn1-por-4-027){ref-type="table-fn"}, n (%)       
   Lower back pain                                                                  431 (6.4)
   Osteoarthritis                                                                   362 (5.3)
  CCI score, mean (SD)                                                              0.97 (1.01)

**Notes:**

Comorbidities occurring in \>5% of patients in the 12 months prior to diagnosis of DPNP. Other diabetes-related comorbidities examined included hypoglycemic events, other metabolic diseases, skin problems, nephropathy, obesity and anxiety. Other pain-related comorbidities examined included fibromyalgia syndrome, migraine, psoriatic arthropathy, and rheumatoid arthritis.

**Abbreviations:** DPNP, diabetic peripheral neuropathic pain; SD, standard deviation; CCI score, Charlson Comorbidity Index score; n, number.

###### 

Incidence of DPNP per 100,000 person-years (95% CI) by sex, age group, and time period

  -----------------------------------------------------------------------------------------------------------------------------------------
                  Subperiod 1\                  Subperiod 2\                  Subperiod 3\
                  July 1, 2002--June 30, 2005   July 1, 2005--June 30, 2008   July 1, 2008--June 30, 2011
  --------------- ----------------------------- ----------------------------- -------------------------------------------------------------
  Total           17.9 (17.1--18.6)             17.2 (16.5--17.9)             18.4 (17.7--19.2)

  Female                                                                      

   0--14 years    --                            --                            --

   15--29 years   0.6 (0.2--1.3)                0.9 (0.4--1.7)                1.2 (0.7--2.1)

   30--44 years   6.4 (5.2--7.9)                5.1 (4.0--6.4)                5.3 (4.1--6.7)

   45--59 years   20.4 (18.0--23.1)             19.1 (16.8--21.6)             20.5 (18.1--23.2)

   60--74 years   48.7 (44.2--53.5)             47.9 (43.6--52.5)             38.7 (34.8--42.8)[\*](#tfn4-por-4-027){ref-type="table-fn"}

   75+ years      48.6 (43.1--54.6)             41.2 (36.2--46.7)             50.2 (44.5--56.4)

  Male                                                                        

   0--14 years    --                            --                            --

   15--29 years   0.7 (0.3--1.3)                0.6 (0.2--1.3)                1.1 (0.6--1.9)

   30--44 years   6.1 (4.9--7.5)                5.4 (4.3--6.7)                5.4 (4.2--6.8)

   45--59 years   26.8 (24.0--29.7)             25.1 (22.5--27.9)             28.4 (25.5--31.5)

   60--74 years   61.9 (56.6--67.5)             61.7 (56.6--67.1)             64.1 (58.9--69.5)

   75+ years      69.9 (61.2--79.4)             67.1 (59.0--76.1)             76.3 (67.5--85.9)
  -----------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Poisson exact CI (95%) are given in brackets.

*P* = 0.001 from Poisson regression for trend of incidence rates.

**Abbreviations:** DPNP, diabetic peripheral neuropathic pain; CI, confidence interval.

###### 

Initial treatment prescribed for incident DPNP by type of medication and study period

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                        Subperiod 1\                              Subperiod 2\                              Subperiod 3\                              Total study period\                                            
                                                    July 1, 2002--June 30, 2005 (n = 1,871)   July 1, 2005--June 30, 2008 (n = 1,940)   July 1, 2008--June 30, 2011 (n = 1,956)   July 1, 2002--June 30, 2011 (n = 5,767)                        
  ------------------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----- ------ ------- ------
  Nonopioid analgesics                              47                                        2.5                                       38                                        2.0                                       46    2.4    131     2.3

  Opioid                                            192                                       10.3                                      170                                       8.8                                       142   7.3    504     8.7

  NSAIDs                                            354                                       18.9                                      297                                       15.3                                      210   10.7   861     14.9

  Anticonvulsants                                   266                                       14.2                                      366                                       18.9                                      350   17.9   982     17.0

  TCAs                                              505                                       27.0                                      490                                       25.3                                      574   29.4   1,569   27.2

  SSRIs                                             28                                        1.5                                       31                                        1.6                                       31    1.6    90      1.6

  SNRIs[\*](#tfn7-por-4-027){ref-type="table-fn"}   1                                         0.1                                       5                                         0.3                                       78    4.0    84      1.5

  Duloxetine                                        0                                         0                                         4                                         0.2                                       75    3.8    79      1.4

  Other antidepressants                             2                                         0.1                                       2                                         0.1                                       7     0.4    11      0.2

  Combination therapy                               476                                       25.4                                      541                                       27.9                                      518   26.5   1,535   26.6
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Data presented are number and percentage of initial prescriptions by type of medication within 28 days of first diagnosis of DPNP for the total study period and each subperiod.

SNRIs consist of duloxetine and venlafaxine. Duloxetine is also listed separately as it is the only SNRI recommended for DPNP. Combination therapy is defined as more than one pharmacotherapy prescribed on the same day.

**Abbreviations:** DPNP, diabetic peripheral neuropathic pain; NSAIDs, nonsteroidal anti-inflammatory drugs; TCA, tricyclic antidepressant; SSRIs, selective serotonin reuptake inhibitors; SNRI, serotonin norepinephrine reuptake inhibitor; n, number.
